BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stawowczyk E, Kawalec P. A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis. Pharmacoeconomics. 2017;36:419-434. [PMID: 29260508 DOI: 10.1007/s40273-017-0601-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Almousa AA, Meurens F, Krol ES, Alcorn J. Linoorbitides and enterolactone mitigate inflammation-induced oxidative stress and loss of intestinal epithelial barrier integrity. International Immunopharmacology 2018;64:42-51. [DOI: 10.1016/j.intimp.2018.08.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
2 Hernandez L, Kuwabara H, Shah A, Yamabe K, Burnett H, Fahrbach K, Koufopoulou M, Iwakiri R. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan. Pharmacoeconomics 2020;38:69-84. [PMID: 31552601 DOI: 10.1007/s40273-019-00841-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhang J, Shi G. Lymphocyte infiltration and key differentially expressed genes in the ulcerative colitis. Medicine (Baltimore) 2020;99:e21997. [PMID: 32871953 DOI: 10.1097/MD.0000000000021997] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Ledesma F, Buti M, Domínguez-Hernández R, Casado MA, Esteban R. Is the universal population Hepatitis C virus screening a cost-effective strategy? A systematic review of the economic evidence. Rev Esp Quimioter 2020;33:240-8. [PMID: 32510188 DOI: 10.37201/req/030.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Niu W, Chen X, Xu R, Dong H, Yang F, Wang Y, Zhang Z, Ju J. Polysaccharides from natural resources exhibit great potential in the treatment of ulcerative colitis: A review. Carbohydr Polym 2021;254:117189. [PMID: 33357839 DOI: 10.1016/j.carbpol.2020.117189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
6 Wu B, Wang Z, Zhang Q. Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis. Inflamm Bowel Dis 2018;24:2291-302. [PMID: 29718241 DOI: 10.1093/ibd/izy114] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
7 Vohra I, Attar B, Haghbin H, Mutneja H, Katiyar V, Sharma S, Abegunde AT, Demetria M, Gandhi S. Incidence and risk factors for 30-day readmission in ulcerative colitis: nationwide analysis in biologic era. Eur J Gastroenterol Hepatol 2021;33:1174-84. [PMID: 34034271 DOI: 10.1097/MEG.0000000000002147] [Reference Citation Analysis]
8 Horiguchi N, Kamoi K, Horie S, Iwasaki Y, Kurozumi-Karube H, Takase H, Ohno-Matsui K. A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet's syndrome. Sci Rep 2020;10:22227. [PMID: 33335139 DOI: 10.1038/s41598-020-78718-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Singh E. Comment on: "A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis". Pharmacoeconomics 2018;36:879. [PMID: 29725873 DOI: 10.1007/s40273-018-0655-0] [Reference Citation Analysis]
10 Chen YL, Zhang YL, Dai YC, Tang ZP. Systems pharmacology approach reveals the antiinflammatory effects of Ampelopsis grossedentata on dextran sodium sulfate-induced colitis. World J Gastroenterol 2018; 24(13): 1398-1409 [PMID: 29632421 DOI: 10.3748/wjg.v24.i13.1398] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
11 Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.Gastroenterology. 2020;158:1465-1496.e17. [PMID: 31945351 DOI: 10.1053/j.gastro.2020.01.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 11.5] [Reference Citation Analysis]
12 Dulai PS, Sandborn WJ, Murphy J. Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Ulcerative Colitis. Clin Gastroenterol Hepatol 2021;19:1170-1179.e10. [PMID: 32437872 DOI: 10.1016/j.cgh.2020.05.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Dulai PS, Jairath V, Narula N, Wong E, Kochhar GS, Colombel JF, Sandborn WJ. A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease. Am J Gastroenterol 2021;116:1709-19. [PMID: 34587127 DOI: 10.14309/ajg.0000000000001263] [Reference Citation Analysis]
14 Dulai PS, Jairath V. A Microsimulation Model to Project the 5-Year Impact of Using Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Acute Flares. Dig Dis Sci 2021;66:3740-52. [PMID: 33185788 DOI: 10.1007/s10620-020-06707-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Sardesai A, Dignass A, Quon P, Milev S, Cappelleri JC, Kisser A, Modesto I, Sharma PP. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany. J Med Econ 2021;24:279-90. [PMID: 33502905 DOI: 10.1080/13696998.2021.1881323] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Danese S, Fiorino G, Peyrin-biroulet L. Positioning Therapies in Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2020;18:1280-1290.e1. [DOI: 10.1016/j.cgh.2020.01.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]